article thumbnail

STAT+: Medicare already covers GLP-1s for half of seniors with obesity, new report finds

STAT

The active ingredients in those drugs also are approved for other conditions, including diabetes and cardiovascular disease, that Medicare does cover.  The Congressional Budget Office estimates that 29 million beneficiaries would qualify for weight loss drugs in 2026.  But a lot of people are switching to GLP-1s.

Diabetes 311
article thumbnail

STAT+: Google’s Verily to offer GLP-1 drugs through Lightpath, its retooled chronic care app

STAT

Lightpath Metabolic, expected to be available in 2026, will not only include programs for people with type 1 and type 2 diabetes and hypertension — as the current iteration of Onduo does — but will also offer GLP-1 drug prescriptions.

Diabetes 303
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmalittle: We’re reading about Amylyx pulling its ALS drug, GLP-1 drugs for Parkinson’s, and more

STAT

… The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, such as mental health disorders, Alzheimer’s, and even, as new study results suggest — Parkinson’s disease , STAT writes.  In

Diabetes 241
article thumbnail

STAT+: Pharmalittle: We’re reading about the aftermath of FDA vote on MDMA, rising pharma layoffs, and more

STAT

… Eli Lilly’s blockbuster diabetes and obesity drug improved liver scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year, STAT tells us. But the patent on semaglutide, the active ingredient in both drugs, expires in China in 2026. So no need to mess with rebates.

Diabetes 257
article thumbnail

Opinion: STAT+: What the newly released Medicare prices for 10 drugs do and don’t tell us

STAT

billion ) in 2026. However, knowing what to make of discounts from list prices ranging from 38% for Imbruvica for blood cancers to 79% for Januvia for diabetes is trickier. Those of us who work in drug pricing daily are closely examining and evaluating the methods used to determine these prices.

article thumbnail

STAT+: Pharmalittle: FDA approves Pfizer’s RSV vaccine for newborns; Boehringer sues over IRA

STAT

Jardiance, a diabetes medicine co-marketed by Boehringer, is expected to be among the first drugs to face negotiation once the law takes effect in 2026. Continue to STAT+ to read the full story…

Vaccines 215
article thumbnail

Cipla strengthens its anti-diabetes portfolio through partnerships with MNCs: GlobalData

Express Pharma

Cipla holds a prominent position in the top five therapy areas in India, except for the anti-diabetes and gastrointestinal segment. Against this backdrop, the Indian pharma major is constantly partnering with multinational companies to get access to an innovative portfolio with a focus on diabetes, says GlobalData.